Lecanemab Alzheimer's Disease Treatment Pros and Cons

One of the biggest challenges with Alzheimer’s is that by the time symptoms become noticeable, the disease has often been progressing for quite some time. A new study suggests a blood test may one day identify people at high risk of developing Alzheimer’s before any symptoms develop. While the test isn’t ready for routine use, the direction of the research is promising. Earlier detection could allow families to prepare sooner, physicians to monitor patients more closely, and, as new therapies continue to emerge, create opportunities to intervene before significant cognitive decline occurs. Some of the most meaningful advances in medicine come from identifying disease earlier not just treating it after symptoms begin. The future of Alzheimer’s care may begin long before the first symptom appears. https://lnkd.in/eBX5Gdfd #Alzheimers #Healthcare #Innovation #Future

I've used this antihistamine protocol on athletes in clinic with suspected post-covid/POTS with impressive results (of course having ruled out other possible causes). One of the earliest published studies mentioned how a nurse who was one of the cases realised antihistamines could improve post-covid when she took Benadryl to counteract an allergic reaction to cheese! https://lnkd.in/e3k7rAHS Otherwise the article by Glynne et al. seems to be the first article to suggest the role of antihistamines in post-covid treatment: https://lnkd.in/edPzT4Eu

New research led by UCL and UCLH has found that commonly used antihistamines and the anti-inflammatory drug colchicine can provide a small short-term improvement in fatigue for people with long COVID receiving specialist care. The trial involved nearly 800 adults across England and highlights both the importance of specialist long COVID services and the need for continued research into effective treatments. Dr Melissa Heightman, clinical lead for the post-Covid service at UCLH, said: “It is heartening that people had a significant reduction in fatigue across all arms of the trial. This is more than you would expect based on time alone, given that participants had severe fatigue at recruitment and been ill for more than a year on average. “This level of improvement shows the importance of specialist long Covid care. These services in England offer integrated care from a range of specialties with community-based rehabilitation to develop a plan for a person based on their symptoms and all of the ways the condition affects them.” Read more: https://buff.ly/iNjhEUr

National Hemochromatosis Awareness Month | Advancing Awareness Through Health Education Iron is essential for several important functions in the body. However, excessive iron accumulation over time can lead to iron overload and affect multiple organs. Hemochromatosis is a condition in which excess iron can build up in the body over time. Depending on the condition and individual circumstances, iron overload may affect organs including the liver, heart, pancreas, and joints. Some individuals may have few or no symptoms in the early stages. Others may experience nonspecific symptoms such as fatigue, weakness, joint pain, or abdominal discomfort. These symptoms can occur in many conditions, making appropriate clinical evaluation important. A family history of hereditary hemochromatosis is an important factor to discuss with a qualified healthcare professional. This National Hemochromatosis Awareness Month, we highlight the importance of health education, appropriate assessment, early recognition, and evidence-based care. At Bagchi Sri Shankara Cancer Centre and Research Institute, our commitment to healthcare is strengthened by clinical expertise, research, innovation, and a patient-centered approach. #HemochromatosisAwareness #Hemochromatosis #IronOverload #HealthEducation #ClinicalExcellence #MedicalResearch #PatientCenteredCare #HealthcareInnovation #BagchiSriShankaraCancerCentre

Conclusion: There has been an increasing trend toward the use of PSMA PET/CT for staging mCSPC in recent years, identifying a population with more favourable disease characteristics and a more favourable prognosis. This shift in patient characteristics, driven by stage migration (the Will Rogers phenomenon), influences clinical management by enabling more refined patient selection for conservative or targeted therapies. Consequently, accounting for lead-time and selection bias is essential when comparing survival outcomes in the PSMA PET/CT era.

To RA clinicians in Northern Ireland, this seems an excellent opportunity to empower your patients by decreasing the number of visits to the clinic.

To better understand how to support individuals through the kidney transplant evaluation process, a PCORI-funded randomized controlled trial compared two approaches for early transplant: 1️⃣ Usual kidney care augmented with best practice alerts 2️⃣ Patient-centered transplant outreach and navigation Results from this study can help hospital and health system administrators determine effective strategies for supporting people with kidney disease through the transplant process. Read more: https://pcori.me/4fK1Q59

As GLP-1 therapies redefine the standards of obesity treatment, they also present a fresh set of challenges that require innovative strategic solutions. Our latest whitepaper offers an in-depth analysis of these complexities and the proactive measures being employed within the industry. Explore the real-world limitations of GLP-1 therapies, including durability issues, lean mass preservation, and incomplete comorbidity coverage. The GLP-1 conversation has now moved beyond weight loss to how to reshape the broader landscape of metabolic healthcare. Key insights: • The journey towards scalable and viable therapy solutions • Cutting-edge innovations transcending traditional treatment approaches • Strategic directions for healthcare professionals and industry stakeholders in adapting to new paradigms 🔗 Click the link to download the full report and gain the insights necessary to navigate this transformative time in healthcare: https://ow.ly/Ew5q30sX1PC

As GLP-1 therapies redefine the standards of obesity treatment, they also present a fresh set of challenges that require innovative strategic solutions. Our latest whitepaper offers an in-depth analysis of these complexities and the proactive measures being employed within the industry. Explore the real-world limitations of GLP-1 therapies, including durability issues, lean mass preservation, and incomplete comorbidity coverage. The GLP-1 conversation has now moved beyond weight loss to how to reshape the broader landscape of metabolic healthcare. Key insights: • The journey towards scalable and viable therapy solutions • Cutting-edge innovations transcending traditional treatment approaches • Strategic directions for healthcare professionals and industry stakeholders in adapting to new paradigms 🔗 Click the link to download the full report and gain the insights necessary to navigate this transformative time in healthcare: https://ow.ly/oCPQ30sX8ZO

Cardiomyopathies are too often unseen, underdiagnosed and undertreated - yet early diagnosis can make a meaningful difference for patients, families and health systems. It enables timely treatment, helps prevent avoidable hospitalizations, reduces long-term costs, and, ultimately, can save lives. That’s why the Cardiomyopathies Matter initiative is so important. By raising awareness and advocating for stronger cardiovascular policies at EU and national levels, it sets out clear actions to advance early diagnosis - from embedding into prevention agendas to improving access to advanced diagnostics, expanding family screening and strengthening awareness of early symptoms. At Philips, we’re proud to support and partner with this initiative to help bring precise diagnosis and connected care to more people, earlier. By working together, we can shorten the time to diagnosis, change life trajectories for patients and their families, and improve cardiovascular health across Europe. 🔗 Read more here: https://lnkd.in/ePTcxzf5    Patricia Tiramani Rogier Veltrop Teofila (Tootie) Bueser